Patent · US Active

Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof

US10336820B2 · kind B2 · utility

0Cited by

68References

17Claims

0Family size

Assignee

AMGEN INC. · US

Inventors

Thomas C. Boone · Newbury Park, US
Jonathan Daniel Oliner · Garrett Park, US
Eunkyung LEE · Seojong-myeon, KR

Key dates

Filing date	Dec 2, 2016
Grant date	Jul 2, 2019
Priority date	—
Expiry date	Dec 2, 2036

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Disclosed are specific binding agents, such as fully human antibodies, that bind to angiopoietin 1 and/or angiopoietin-2. Also disclosed are heavy chain fragments, light chain fragments, and CDRs of the antibodies, as well as methods of making and using the antibodies.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.